Know Cancer

or
forgot password

Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors


Phase 1
9 Years
N/A
Not Enrolling
Both
Sarcoma, Ewing's

Thank you

Trial Information

Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors


Inclusion Criteria:



- Diagnosis of Ewing's sarcoma family tumors

Exclusion Criteria:

- Concurrent treatment with any other anti tumor agents

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability of CP-751,871

Outcome Time Frame:

approximately 76 months

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4021010

NCT ID:

NCT00474760

Start Date:

August 2005

Completion Date:

October 2012

Related Keywords:

  • Sarcoma, Ewing's
  • Sarcoma, Ewing's
  • Sarcoma

Name

Location

Pfizer Investigational SiteDetroit, Michigan  48201
Pfizer Investigational SiteRochester, Minnesota  55905